A JAK2 mutation is a change in the gene that can cause uncontrolled blood cell production. JAK2 mutations are linked to blood cancers and disorders like polycythemia vera and essential thrombocythemia ...

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

The JAK2 gene mutation discovery led to JAK inhibitors, transforming myelofibrosis treatment by targeting the JAK-STAT pathway. Four FDA-approved JAK inhibitors for myelofibrosis include Jakafi, ...

Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...

ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...

The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...

Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set. Mutations may ...